Licensed influenza vaccine

BIOLOGICAL6 trials

Sponsors

Mahidol University, BioNTech SE, Pfizer, ModernaTX, Inc., GlaxoSmithKline

Conditions

COVID-19GrippeInfluenzaInfluenza, HumanVaccines

Phase 1

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

CompletedNCT06179446

PfizerGrippe, Influenza, Vaccines

Start: 2023-12-13End: 2025-09-23Updated: 2026-02-23

Phase 2

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

CompletedNCT03390166

Mahidol UniversityInfluenza

Start: 2017-07-24End: 2019-02-12Updated: 2020-04-14

Phase 3

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly

Mahidol UniversityInfluenza

Start: 2020-08-03End: 2023-12-31Target: 816Updated: 2022-08-25

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

CompletedNCT06178991

BioNTech SECOVID-19, Influenza

Start: 2023-12-20End: 2024-11-26Updated: 2025-12-04

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

CompletedNCT06694389

ModernaTX, Inc.COVID-19, Influenza

Start: 2024-11-18End: 2025-11-17Updated: 2025-12-02

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

RecruitingNCT07805707

GlaxoSmithKlineInfluenza, Human

Start: 2026-09-02End: 2028-06-09Target: 54000Updated: 2026-09-18

Related Papers

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults

Vaccines2026-08-05

Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan.

2026-07-30